drugset / Trial / NCT04826393
ASP8374 + Cemiplimab in Recurrent Glioma
Phase 1
Completed
14 enrolled
Dana-Farber Cancer Institute
Astellas Pharma Inc · collabRegeneron Pharmaceuticals · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
This study is looking at the safety and efficacy of the drug combination of ASP8374 with cemiplimab in people with recurrent malignant glioma. The study will be conducted in two parts, the first portion of the study will be to establish the highest dose of ASP8374 that can be given safely with cemiplimab and will be used as the recommended dose of ASP8374 in combination with cemiplimab for the second portion of the study. The second portion of the study will be to compare the effect of having ASP8374 in combination with cemiplimab prior to surgery. The names of the study drugs involved in this study are: * ASP8374 * Cemiplimab
Timeline
- Start
- 2022-03-09
- Primary completion
- 2022-10-31
- Completion
- 2024-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASP8374 | Unknown | — | Intravenous |
| Subject | Cemiplimab | Monoclonal antibody | — | Intravenous |